Published in Am Heart J on January 01, 2011
Role of Immune Responses After Acute Myocardial Infarction (BATTLE-AMI) | NCT02428374
Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation (2012) 4.56
Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes. Circ Res (2014) 2.46
Adult Bone Marrow Cell Therapy for Ischemic Heart Disease: Evidence and Insights From Randomized Controlled Trials. Circ Res (2015) 1.80
Sonic hedgehog-modified human CD34+ cells preserve cardiac function after acute myocardial infarction. Circ Res (2012) 1.70
Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res (2015) 1.57
Circulating CD34+ progenitor cells and risk of mortality in a population with coronary artery disease. Circ Res (2014) 1.54
The advancing field of cell-based therapy: insights and lessons from clinical trials. J Am Heart Assoc (2013) 1.40
Frequency of discrepancies in retracted clinical trial reports versus unretracted reports: blinded case-control study. BMJ (2015) 1.39
Circulating CD34(+) progenitor cell frequency is associated with clinical and genetic factors. Blood (2013) 1.07
Long-term effects of autologous bone marrow stem cell treatment in acute myocardial infarction: factors that may influence outcomes. PLoS One (2012) 1.05
Comparison of human adipose-derived stem cells isolated from subcutaneous, omental, and intrathoracic adipose tissue depots for regenerative applications. Stem Cells Transl Med (2013) 0.96
Effects of acute and chronic endurance exercise on intracellular nitric oxide and superoxide in circulating CD34⁺ and CD34⁻ cells. J Appl Physiol (1985) (2011) 0.95
Key developments in stem cell therapy in cardiology. Regen Med (2012) 0.92
Current stem cell delivery methods for myocardial repair. Biomed Res Int (2012) 0.89
Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease. Stem Cells Transl Med (2015) 0.87
Potential Strategies to Address the Major Clinical Barriers Facing Stem Cell Regenerative Therapy for Cardiovascular Disease: A Review. JAMA Cardiol (2016) 0.86
Age and Human Regenerative Capacity Impact of Cardiovascular Risk Factors. Circ Res (2016) 0.86
Transcriptome analysis reveals transmembrane targets on transplantable midbrain dopamine progenitors. Proc Natl Acad Sci U S A (2015) 0.85
Molecular imaging: the key to advancing cardiac stem cell therapy. Trends Cardiovasc Med (2013) 0.83
Optimized processing of growth factor mobilized peripheral blood CD34+ products by counterflow centrifugal elutriation. Stem Cells Transl Med (2012) 0.82
Fractalkine expression induces endothelial progenitor cell lysis by natural killer cells. PLoS One (2011) 0.81
Characterization of mechanical dyssynchrony measured by gated single photon emission computed tomography phase analysis after acute ST-elevation myocardial infarction. J Nucl Cardiol (2011) 0.77
Impact of Timing following Acute Myocardial Infarction on Efficacy and Safety of Bone Marrow Stem Cells Therapy: A Network Meta-Analysis. Stem Cells Int (2015) 0.77
Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34(+) Bone Marrow Mononuclear Cells. Stem Cells Int (2013) 0.77
Clinical trials of cardiac repair with adult bone marrow- derived cells. Methods Mol Biol (2013) 0.77
Stem cell therapy for cardiovascular disease: the demise of alchemy and rise of pharmacology. Br J Pharmacol (2013) 0.76
A Detailed Assessment of Varying Ejection Rate on Delivery Efficiency of Mesenchymal Stem Cells Using Narrow-Bore Needles. Stem Cells Transl Med (2016) 0.76
Effects of clopidogrel therapy on oxidative stress, inflammation, vascular function, and progenitor cells in stable coronary artery disease. J Cardiovasc Pharmacol (2014) 0.76
Stem Cells and Cloning: Advances and Applications 2015:8 135-148. Stem Cells Cloning (2015) 0.76
Vascular stem cells-potential for clinical application. Br Med Bull (2016) 0.75
Assessment of Myocardial Contractile Function Using Global and Segmental Circumferential Strain following Intracoronary Stem Cell Infusion after Myocardial Infarction: MRI Feature Tracking Feasibility Study. ISRN Radiol (2012) 0.75
What Is the Future of Cell-Based Therapy for Acute Myocardial Infarction. Circ Res (2017) 0.75
Molecular imaging of stem cells for the treatment of acute myocardial infarction. Int J Clin Exp Med (2015) 0.75
Discrepancy between short-term and long-term effects of bone marrow-derived cell therapy in acute myocardial infarction: a systematic review and meta-analysis. Stem Cell Res Ther (2016) 0.75
Fifteen years of bone marrow mononuclear cell therapy in acute myocardial infarction. World J Stem Cells (2017) 0.75
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation (2006) 11.78
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med (2012) 6.30
Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med (2008) 5.86
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA (2003) 5.39
Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med (2015) 4.85
Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol (2002) 4.56
ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2012) 4.45
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Clinical features, management, and prognosis of spontaneous coronary artery dissection. Circulation (2012) 4.13
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol (2013) 3.77
The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol (2004) 3.61
Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation (2007) 3.57
Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol (2004) 3.47
Natural history of asymptomatic mitral valve prolapse in the community. Circulation (2002) 3.40
Controversies in ventricular remodelling. Lancet (2006) 3.39
Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. J Am Coll Cardiol (2003) 3.20
Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med (2002) 3.17
Familial atrial fibrillation is a genetically heterogeneous disorder. J Am Coll Cardiol (2003) 3.09
Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation (2003) 2.99
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol (2010) 2.99
Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol (2010) 2.93
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol (2013) 2.90
Controversies in stable coronary artery disease. Lancet (2006) 2.88
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet (2009) 2.82
Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol (2008) 2.74
Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin. Mol Genet Metab (2005) 2.72
Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation. N Engl J Med (2003) 2.68
Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation (2010) 2.64
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol (2010) 2.55
Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter? J Am Coll Cardiol (2006) 2.55
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2011) 2.53
Trends in cause of death after percutaneous coronary intervention. Circulation (2014) 2.52
Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol (2002) 2.50
Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol (2011) 2.49
Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol (2005) 2.49
Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation (2007) 2.47
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol (2005) 2.43
Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation (2008) 2.42
Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood (2008) 2.34
Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol (2007) 2.32
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood (2003) 2.31
Syncope while driving: clinical characteristics, causes, and prognosis. Circulation (2009) 2.30
Aborted myocardial infarction: a new target for reperfusion therapy. Eur Heart J (2006) 2.26
Noninvasive estimation of left ventricular filling pressure by E/e' is a powerful predictor of survival after acute myocardial infarction. J Am Coll Cardiol (2004) 2.25
Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S aureus and methicillin-resistant S aureus bacteremia. Am Heart J (2004) 2.25
Sudden death after myocardial infarction. JAMA (2008) 2.24
Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation (2007) 2.20
The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol (2003) 2.19
Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol (2010) 2.15
Effect of peripheral arterial disease in patients undergoing percutaneous coronary intervention with intracoronary stents. Mayo Clin Proc (2004) 2.11
Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc (2002) 2.08
Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation (2002) 2.07
Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation (2003) 2.05
Accurate assessment of aortic stenosis: a review of diagnostic modalities and hemodynamics. Circulation (2014) 2.04
Syncope Evaluation in the Emergency Department Study (SEEDS): a multidisciplinary approach to syncope management. Circulation (2004) 2.04
Incidence of heart failure after myocardial infarction: is it changing over time? Am J Epidemiol (2003) 2.03
Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J (2008) 2.03
Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J Am Coll Cardiol (2002) 2.02
Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation (2006) 2.01
Diagnostic performance of fusion of myocardial perfusion imaging (MPI) and computed tomography coronary angiography. J Nucl Cardiol (2009) 1.99
Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol (2012) 1.98
Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades. Eur Heart J (2006) 1.97
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood (2005) 1.95
Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J (2007) 1.92
Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol (2007) 1.91
Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv (2012) 1.89
Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Biol Blood Marrow Transplant (2007) 1.89
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant (2013) 1.88
Left atrial volume predicts the risk of atrial fibrillation after cardiac surgery: a prospective study. J Am Coll Cardiol (2006) 1.88
Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant (2011) 1.88
Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail (2009) 1.87
Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. J Am Coll Cardiol (2004) 1.84
Usefulness of left atrial volume in predicting first congestive heart failure in patients > or = 65 years of age with well-preserved left ventricular systolic function. Am J Cardiol (2005) 1.84
Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2004) 1.83
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J (2010) 1.82
Atherosclerotic lesions grow through recruitment and proliferation of circulating monocytes in a murine model. Am J Pathol (2002) 1.80
Mortality differences between men and women after percutaneous coronary interventions. A 25-year, single-center experience. J Am Coll Cardiol (2008) 1.78
Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation (2012) 1.77
Heart failure after myocardial infarction: a review. Am J Med (2002) 1.76
Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol (2011) 1.72